Kathryn Rudd

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1676125/publications.pdf Version: 2024-02-01



Κλτήρνη Ρυσο

#	Article	IF	CITATIONS
1	Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Predict the Cardiotoxicity Potential of Next Generation Nicotine Products. Frontiers in Toxicology, 2022, 4, 747508.	3.1	4
2	Preclinical Assessment of Tobacco-Free Nicotine Pouches Demonstrates Reduced <i>In Vitro</i> Toxicity Compared with Tobacco Snus and Combustible Cigarette Smoke. Applied in Vitro Toxicology, 2022, 8, 24-35.	1.1	10
3	A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobacco-free oral nicotine pouches relative to cigarettes. Psychopharmacology, 2022, 239, 2931-2943.	3.1	8
4	Use of a rapid human primary cell-based disease screening model, to compare next generation products to combustible cigarettes. Current Research in Toxicology, 2021, 2, 309-321.	2.7	3
5	Multi-endpoint analysis of human 3D airway epithelium following repeated exposure to whole electronic vapor product aerosol or cigarette smoke. Current Research in Toxicology, 2021, 2, 99-115.	2.7	13
6	The <i>in vitro</i> ToxTracker and Aneugen Clastogen Evaluation extension assay as a tool in the assessment of relative genotoxic potential of e-liquids and their aerosols. Mutagenesis, 2021, 36, 129-142.	2.6	12
7	The use of human induced pluripotent stem cells to screen for developmental toxicity potential indicates reduced potential for non-combusted products, when compared to cigarettes. Current Research in Toxicology, 2020, 1, 161-173.	2.7	10
8	Chemical Composition and <i>In Vitro</i> Toxicity Profile of a Pod-Based E-Cigarette Aerosol Compared to Cigarette Smoke. Applied in Vitro Toxicology, 2020, 6, 11-41.	1.1	31